

# Dave Singh

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1877667/dave-singh-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

358 papers	14,739 citations	59 h-index	110 g-index
446 ext. papers	18,601 ext. citations	7.3 avg, IF	6.85 L-index

#	Paper	IF	Citations
358	New Drugs for Airway Diseases <b>2022</b> , 741-753		
357	Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.. <i>International Journal of COPD</i> , <b>2022</b> , 17, 355-370	3	0
356	Sputum cell counts in COPD patients who use electronic cigarettes.. <i>European Respiratory Journal</i> , <b>2022</b> ,	13.6	0
355	New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management.. <i>Advances in Therapy</i> , <b>2022</b> , 1	4.1	2
354	COPD lung studies of Nrf2 expression and the effects of Nrf2 activators.. <i>Inflammopharmacology</i> , <b>2022</b> , 1	5.1	1
353	Normalisation of airflow limitation in asthma: Post-hoc analyses of TRIMARAN and TRIGGER.. <i>Clinical and Translational Allergy</i> , <b>2022</b> , 12, e12145	5.2	
352	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.. <i>Respiratory Medicine</i> , <b>2022</b> , 197, 106857	4.6	0
351	Dexamethasone and p38 MAPK inhibition of cytokine production from human lung fibroblasts. <i>Fundamental and Clinical Pharmacology</i> , <b>2021</b> , 35, 714-724	3.1	2
350	The relationship between airway immunoglobulin activity and eosinophils in COPD. <i>Journal of Cellular and Molecular Medicine</i> , <b>2021</b> , 25, 2203-2212	5.6	5
349	Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	2
348	Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. <i>Drugs</i> , <b>2021</b> , 81, 1821-1830	12.1	0
347	The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN). <i>Journal of Immunological Methods</i> , <b>2021</b> , 500, 113181	2.5	
346	Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 740803	5.6	5
345	Treatment Trials in Young Patients with COPD and Pre-COPD Patients: Time to Move Forward. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	7
344	Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals. <i>International Journal of COPD</i> , <b>2021</b> , 16, 3009-3016	3	1
343	Reply to: Revaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies? <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 577-578	3.8	2
342	Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 1861-1864	9.3	12

341	Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 1488-1502	10.2	21
340	Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and infection in COPD. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	8
339	Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. <i>Respiratory Research</i> , <b>2021</b> , 22, 90	7.3	2
338	InforMing the PATHway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. <i>Respiratory Research</i> , <b>2021</b> , 22, 130	7.3	2
337	Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis.. <i>Lancet Microbe</i> , <b>2021</b> , 2, e300-e310	22.2	8
336	Pharmacological treatment of stable chronic obstructive pulmonary disease. <i>Respirology</i> , <b>2021</b> , 26, 643-651	5	
335	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 788-798	4.7	6
334	Reply to: "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Letter]. <i>International Journal of COPD</i> , <b>2021</b> , 16, 1299-1301	3	
333	Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes. <i>Scientific Reports</i> , <b>2021</b> , 11, 12848	4.9	0
332	Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. <i>Expert Review of Respiratory Medicine</i> , <b>2021</b> , 15, 1093-1106	3.8	0
331	Future concepts in bronchodilation for COPD: dual- monotherapy. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	1
330	Type-2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 1259-1264	4.9	5
329	A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	13
328	Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 262-265.e2	11.5	3
327	Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 483-493	3.8	12
326	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. <i>Chest</i> , <b>2021</b> , 159, 985-995	5.3	2
325	Remote FEV1 Monitoring in Asthma Patients: A Pilot Study. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 529-535	4.9	3
324	Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. <i>Pulmonary Therapy</i> , <b>2021</b> , 7, 101-118	3	2

323	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 553-564	10.2	38
322	Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO Trials. <i>Advances in Therapy</i> , <b>2021</b> , 38, 579-593	4.1	4
321	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 196-206	35.1	219
320	COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum. <i>Journal of Cellular and Molecular Medicine</i> , <b>2021</b> , 25, 905-918	5.6	5
319	Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 626-635	8.6	48
318	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	3
317	Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker. <i>PLoS ONE</i> , <b>2021</b> , 16, e0246627	3.7	3
316	Inhaled long-acting muscarinic antagonists in asthma - A narrative review. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 85, 14-22	3.9	8
315	Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	5
314	Letter to editor - a response to: Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review? <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 939-941	4	1
313	Assessment of bacterial exposure on phagocytic capability and surface marker expression of sputum macrophages and neutrophils in COPD patients. <i>Clinical and Experimental Immunology</i> , <b>2021</b> , 206, 99-109	6.2	1
312	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , <b>2021</b> , 16, 2301-2322	3	2
311	A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	1
310	The novel bronchodilator navafenterol: a phase 2a, multi-centre, randomised, double-blind, placebo-controlled crossover trial in COPD. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	4
309	Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	9.3	3
308	Airway Bacteria Quantification Using Polymerase Chain Reaction Combined with Neutrophil and Eosinophil Counts Identifies Distinct COPD Endotypes. <i>Biomedicine</i> , <b>2021</b> , 9,	4.8	1
307	Improvements in lung function with budesonide/glycopyrrrolate/formoterol fumarate metered dose inhaler dual therapies in patients with COPD: a sub-study of the ETHOS trial. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2021</b> , 15, 17534666211034329	4.9	3
306	Pharmacology Versus Convenience: A Benefit/Risk Analysis of Regular Maintenance Versus Infrequent or As-Needed Inhaled Corticosteroid Use in Mild Asthma. <i>Advances in Therapy</i> , <b>2021</b> , 39, 706	4.1	2

305	Red Blood Cell-Derived Iron Alters Macrophage Function in COPD.. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	4
304	Impact of Body Mass Index Change on the Prognosis of Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , <b>2020</b> , 99, 943-953	3.7	4
303	The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD. <i>Respiratory Research</i> , <b>2020</b> , 21, 323	7.3	2
302	Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. <i>Respiratory Research</i> , <b>2020</b> , 21, 285	7.3	7
301	COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	9
300	Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight. <i>Obesity</i> , <b>2020</b> , 28, 1586-1589	8	46
299	Stability of eosinophilic inflammation in COPD bronchial biopsies. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	9
298	Extrafine triple therapy in patients with asthma and persistent airflow limitation. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	6
297	Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO and OTEMTO Studies. <i>Advances in Therapy</i> , <b>2020</b> , 37, 3485-3499	4.1	6
296	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 35-48	59.2	121
295	Measuring disease activity in COPD: is clinically important deterioration the answer?. <i>Respiratory Research</i> , <b>2020</b> , 21, 134	7.3	10
294	Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. <i>Respiratory Research</i> , <b>2020</b> , 21, 139	7.3	3
293	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 660-671	10.2	33
292	Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. <i>Respiratory Research</i> , <b>2020</b> , 21, 72	7.3	12
291	Goals of COPD treatment: Focus on symptoms and exacerbations. <i>Respiratory Medicine</i> , <b>2020</b> , 166, 105938	13.6	44
290	Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 1508-1516	10.2	63
289	ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. <i>ERJ Open Research</i> , <b>2020</b> , 6,	3.5	3
288	The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 202, 1237-1243	10.2	14

287	Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	17
286	A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. <i>Respiratory Research</i> , <b>2020</b> , 21, 47	7.3	17
285	P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells. <i>Journal of Molecular Medicine</i> , <b>2020</b> , 98, 361-374	5.5	14
284	The stability of blood Eosinophils in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2020</b> , 21, 15	7.3	20
283	Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. <i>Respiratory Research</i> , <b>2020</b> , 21, 17	7.3	9
282	Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240964	3.7	1
281	Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects. <i>Tuberculosis and Respiratory Diseases</i> , <b>2020</b> , 83, 185-194	3.2	5
280	Stability of eosinophilic inflammation in COPD bronchial biopsies. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	2
279	Identifying small airway dysfunction in asthma in clinical practice. <i>Jornal Brasileiro De Pneumologia</i> , <b>2020</b> , 46, e20200046	1.1	1
278	Effects of corticosteroids on COPD lung macrophage phenotype and function. <i>Clinical Science</i> , <b>2020</b> , 134, 751-763	6.5	8
277	A phase 1/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 723-733	3.8	14
276	A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. <i>Clinical and Experimental Allergy</i> , <b>2020</b> , 50, 189-197	4.1	12
275	Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 370-380	9.3	16
274	Asthma control and COPD symptom burden in patients using fixed-dose combination inhalers (SPRINT study). <i>Npj Primary Care Respiratory Medicine</i> , <b>2020</b> , 30, 1	3.2	11
273	FEV recovery following methacholine challenge in asthma: Variability and comparison of methods. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2020</b> , 60, 101876	3.5	0
272	Small airway disease in chronic obstructive pulmonary disease: insights and implications for the clinician. <i>Current Opinion in Pulmonary Medicine</i> , <b>2020</b> , 26, 162-168	3	5
271	Resistome analyses of sputum from COPD and healthy subjects reveals bacterial load-related prevalence of target genes. <i>Thorax</i> , <b>2020</b> , 75, 8-16	7.3	9
270	Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When?. <i>Clinics in Chest Medicine</i> , <b>2020</b> , 41, 463-474	5.3	5



269	Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1065-1066	35.1	12
268	Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. <i>Respiratory Research</i> , 2020, 21, 177	7.3	8
267	The sputum microbiome is distinct between COPD and health, independent of smoking history. <i>Respiratory Research</i> , 2020, 21, 183	7.3	26
266	ADAM15 expression is increased in lung CD8 T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. <i>Respiratory Research</i> , 2020, 21, 188	7.3	3
265	Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials. <i>Advances in Therapy</i> , 2020, 37, 4175-4189	4.1	10
264	Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. <i>Advances in Therapy</i> , 2020, 37, 3775-3790	4.1	1
263	Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study. <i>International Journal of COPD</i> , 2020, 15, 2739-2750	3	
262	COVID-19 and COPD: a narrative review of the basic science and clinical outcomes. <i>European Respiratory Review</i> , 2020, 29,	9.8	25
261	Current developments and future directions in COPD. <i>European Respiratory Review</i> , 2020, 29,	9.8	2
260	A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD. <i>International Journal of COPD</i> , 2020, 15, 3093-3103	3	
259	Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. <i>Respiratory Research</i> , 2020, 21, 289	7.3	15
258	Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study. <i>Respiratory Research</i> , 2020, 21, 246	7.3	10
257	Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. <i>Respiratory Research</i> , 2020, 21, 240	7.3	14
256	Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO/DYNAGITO Trials. <i>Advances in Therapy</i> , 2020, 37, 4266-4279	4.1	4
255	Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. <i>Respiratory Research</i> , 2020, 21, 102	7.3	7
254	Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis. <i>International Journal of COPD</i> , 2020, 15, 2199-2206	3	3
253	Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. <i>Life</i> , 2020, 10,	3	5
252	Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma. <i>Cytokine</i> , 2020, 125, 154857	4	11

251	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 158-170	35.1	35
250	DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT). <i>Journal of Asthma</i> , <b>2020</b> , 57, 1110-1118	1.9	3
249	The effect of exacerbation history on outcomes in the IMPACT trial. <i>European Respiratory Journal</i> , <b>2020</b> , 55,	13.6	9
248	Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study. <i>Respiratory Research</i> , <b>2020</b> , 21, 87	7.3	4
247	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 µg and 160/18/9.6 µg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. <i>Respiratory Medicine</i> , <b>2019</b> , 158, 59-66	4.6	16
246	Reproducibility of nasal allergen challenge responses in adults with allergic rhinitis. <i>Clinical Pharmacology: Advances and Applications</i> , <b>2019</b> , 11, 67-76	1.5	2
245	Circadian rhythm of exhaled biomarkers in health and asthma. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	24
244	Airway host-microbiome interactions in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2019</b> , 20, 113	7.3	47
243	High frequency of infection of lung cancer patients with the parasite. <i>ERJ Open Research</i> , <b>2019</b> , 5,	3.5	5
242	Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2019</b> , 13, 1753466619850725	4.9	325
241	Benralizumab for the Prevention of COPD Exacerbations. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1023-1034	59.2	94
240	Research highlights from the 2018 European Respiratory Society International Congress: airway disease. <i>ERJ Open Research</i> , <b>2019</b> , 5,	3.5	3
239	Reply to Pouwels : Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 114-115	10.2	
238	Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. <i>International Journal of COPD</i> , <b>2019</b> , 14, 479-491	3	4
237	Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. <i>International Journal of COPD</i> , <b>2019</b> , 14, 531-546	3	13
236	Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 402-416	35.1	108
235	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	722
234	The pathology of small airways disease in COPD: historical aspects and future directions. <i>Respiratory Research</i> , <b>2019</b> , 20, 49	7.3	73



233	Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	7
232	A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 1282-1284	10.2	11
231	Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. <i>Cytokine</i> , <b>2019</b> , 113, 68-73	4	9
230	Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 313-320	10.2	44
229	Rhinovirus-16 induced temporal interferon responses in nasal epithelium links with viral clearance and symptoms. <i>Clinical and Experimental Allergy</i> , <b>2019</b> , 49, 1587-1597	4.1	16
228	Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. <i>Respiratory Research</i> , <b>2019</b> , 20, 180	7.3	31
227	The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. <i>Cytokine</i> , <b>2019</b> , 123, 154739	4	20
226	Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. <i>Respiratory Research</i> , <b>2019</b> , 20, 141	7.3	9
225	Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2019</b> , 20, 132	7.3	4
224	Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 745-756	35.1	85
223	Blood eosinophil counts in COPD patients compared to controls. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	11
222	Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. <i>Lancet, The</i> , <b>2019</b> , 394, 1737-1749	40	73
221	Misinterpretation of time-to-first event curves can lead to inappropriate treatment. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	4
220	Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma <b>2019</b> ,		2
219	Comparative effectiveness of triple therapy dual bronchodilation in COPD. <i>ERJ Open Research</i> , <b>2019</b> , 5,	3.5	12
218	High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls. <i>Scientific Reports</i> , <b>2019</b> , 9, 20158	4.9	
217	Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study. <i>Respiratory Research</i> , <b>2019</b> , 20, 288	7.3	13
216	An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD. <i>International Journal of COPD</i> , <b>2019</b> , 14, 2835-2848	3	13

215	Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 729-736	3.8	4
214	Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 199, 1195-1204	10.2	49
213	Effects of baseline symptom burden on treatment response in COPD. <i>International Journal of COPD</i> , <b>2019</b> , 14, 181-194	3	7
212	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 29-39	4.7	8
211	Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. <i>Respiratory Research</i> , <b>2019</b> , 20, 4	7.3	9
210	Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2018</b> , 12, 1753465818755091	4.9	21
209	Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1671-1680	59.2	511
208	Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 49, 27-35	3.5	3
207	Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 1076-1084	40	300
206	Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPD MAP study. <i>Thorax</i> , <b>2018</b> , 73, 331-338	7.3	67
205	The reproducibility of COPD blood eosinophil counts. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	35
204	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 2037-2047.e10	11.5	95
203	Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 739-750	10.2	40
202	Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 71-79	3.5	28
201	Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells. <i>International Journal of COPD</i> , <b>2018</b> , 13, 1279-1288	3	15
200	The Human Virome Protein Cluster Database (HVPC): A Human Viral Metagenomic Database for Diversity and Function Annotation. <i>Frontiers in Microbiology</i> , <b>2018</b> , 9, 1110	5.7	12
199	Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1279-1287	4	2
198	A Disintegrin and Metalloproteinase Domain-8: A Novel Protective Proteinase in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 1254-1267	10.2	19

197	PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge. <i>Biomarker Research</i> , <b>2018</b> , 6, 14	8	16
196	The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages. <i>International Journal of COPD</i> , <b>2018</b> , 13, 771-780	3	17
195	The effect of electronic cigarette and tobacco smoke exposure on COPD bronchial epithelial cell inflammatory responses. <i>International Journal of COPD</i> , <b>2018</b> , 13, 989-1000	3	40
194	A Disintegrin and A Metalloproteinase-9 (ADAM9): A Novel Proteinase Culprit with Multifarious Contributions to COPD. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> ,	10.2	16
193	Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT <b>2018</b> ,		2
192	Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomised controlled study. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 1220-1230	11.5	24
191	Attached stratified mucus separates bacteria from the epithelial cells in COPD lungs. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	25
190	The Manchester Respiratory-related Sleep Symptoms scale for patients with COPD: development and validation. <i>International Journal of COPD</i> , <b>2018</b> , 13, 3885-3894	3	2
189	Inhaled triple therapy in chronic obstructive pulmonary disease - AuthorsPreply. <i>Lancet, The</i> , <b>2018</b> , 392, 1113-1114	40	0
188	The dose response of inhaled LPS challenge in healthy subjects. <i>European Journal of Inflammation</i> , <b>2018</b> , 16, 205873921878482	0.3	1
187	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	102
186	Inhaled corticosteroid containing combinations and mortality in COPD. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	36
185	Feasibility and challenges of using multiple breath washout in COPD. <i>International Journal of COPD</i> , <b>2018</b> , 13, 2113-2119	3	24
184	Time of Day Affects Eosinophil Biomarkers in Asthma: Implications for Diagnosis and Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 1578-1581	10.2	33
183	The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	24
182	The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 2097-2105	3.8	5
181	Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 499-510	35.1	74
180	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Respirology</i> , <b>2017</b> , 22, 575-601	3.6	228

179	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	398
178	Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2017</b> , 42, 43-51	3.5	5
177	Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 710-719	11.5	40
176	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 557-582	10.2	1682
175	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 128-149	0.7	27
174	Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 1181-1184.e7	11.5	52
173	Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. <i>Respiratory Research</i> , <b>2017</b> , 18, 73	7.3	25
172	An investigation of the anti-inflammatory effects and a potential biomarker of PI3K inhibition in COPD T cells. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2017</b> , 44, 932-940	3	8
171	Triple Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1082-1083	10.2	4
170	Impaired Mitochondrial Microbicidal Responses in Chronic Obstructive Pulmonary Disease Macrophages. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 845-855	10.2	51
169	Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , <b>2017</b> , 389, 1919-1929	40	235
168	Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD. <i>Npj Primary Care Respiratory Medicine</i> , <b>2017</b> , 27, 13	3.2	3
167	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. <i>Archivos De Bronconeumologia</i> , <b>2017</b> , 53, 128-149	0.7	247
166	Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management. <i>Advances in Therapy</i> , <b>2017</b> , 34, 281-299	4.1	22
165	Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease. Blood Eosinophils Gain Momentum. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1098-1100	10.2	11
164	RV568, a narrow-spectrum kinase inhibitor with p38 MAPK- and -selectivity, suppresses COPD inflammation. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	26
163	Clinical characteristics of COPD patients with tidal expiratory flow limitation. <i>International Journal of COPD</i> , <b>2017</b> , 12, 1503-1506	3	11
162	Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , <b>2017</b> , 80, 317-324	3.2	15

161	CRTH2 antagonists in asthma: current perspectives. <i>Clinical Pharmacology: Advances and Applications</i> , <b>2017</b> , 9, 165-173	1.5	22
160	Mechanisms of corticosteroid insensitivity in COPD alveolar macrophages exposed to NTHi. <i>Respiratory Research</i> , <b>2017</b> , 18, 61	7.3	20
159	COPD monocytes demonstrate impaired migratory ability. <i>Respiratory Research</i> , <b>2017</b> , 18, 90	7.3	13
158	The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study. <i>International Journal of COPD</i> , <b>2017</b> , 12, 3263-3271	3	3
157	Ampicillin resistance in from COPD patients in the UK. <i>International Journal of COPD</i> , <b>2017</b> , 12, 1507-1518	3	16
156	Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2001-2014	3	7
155	Evaluation of New Drugs for Asthma and COPD: Endpoints, Biomarkers and Clinical Trial Design. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 237, 243-264	3.2	5
154	Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. <i>Advances in Therapy</i> , <b>2017</b> , 33, 2188-2199	4.1	31
153	Characterisation of lung macrophage subpopulations in COPD patients and controls. <i>Scientific Reports</i> , <b>2017</b> , 7, 7143	4.9	48
152	Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients. <i>BMC Pulmonary Medicine</i> , <b>2017</b> , 17, 42	3.5	11
151	Blood and sputum eosinophils in COPD; relationship with bacterial load. <i>Respiratory Research</i> , <b>2017</b> , 18, 88	7.3	72
150	Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. <i>Respiratory Research</i> , <b>2017</b> , 18, 106	7.3	23
149	Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. <i>Biomarker Insights</i> , <b>2017</b> , 12, 1177271917730306	3.5	2
148	Perception of symptoms and quality of life - comparison of patients and physicians' views in the COPD MIRROR study. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2189-2196	3	31
147	LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. <i>International Journal of COPD</i> , <b>2017</b> , 12, 907-922	3	85
146	Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. <i>International Journal of COPD</i> , <b>2017</b> , 12, 2917-2928	3	23
145	Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome. <i>PLoS ONE</i> , <b>2017</b> , 12, e0180859	3.7	27
144	The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD. <i>Lung</i> , <b>2016</b> , 194, 889-895	2.9	19



143	Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 194, 541-9	10.2	47
142	Single inhaler triple therapy versus inhaled corticosteroid plus long-acting $\beta$ -agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. <i>Lancet, The</i> , <b>2016</b> , 388, 963-73	4.0	256
141	Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2016</b> , 176, 1630-1637	11.5	73
140	Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. <i>Respiratory Research</i> , <b>2016</b> , 17, 112	7.3	39
139	Extrafine beclometasone dipropionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. <i>Npj Primary Care Respiratory Medicine</i> , <b>2016</b> , 26, 16030	3.2	19
138	Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells. <i>Respiratory Research</i> , <b>2016</b> , 17, 9	7.3	15
137	Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 37, 9-14	3.5	6
136	The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). <i>Respiratory Medicine</i> , <b>2016</b> , 114, 84-90	4.6	15
135	Electronic cigarette exposure triggers neutrophil inflammatory responses. <i>Respiratory Research</i> , <b>2016</b> , 17, 56	7.3	80
134	Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. <i>Respiratory Medicine</i> , <b>2016</b> , 112, 65-74	4.6	54
133	Now We Know Who You Are: A Clear Description of Mononuclear Phagocyte Subsets in the Human Lung. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 193, 594-6	10.2	4
132	Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD. <i>PLoS ONE</i> , <b>2016</b> , 11, e0163139	3.7	41
131	Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention. <i>Annals of Translational Medicine</i> , <b>2016</b> , 4, 531	3.2	3
130	A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial). <i>Efficacy and Mechanism Evaluation</i> , <b>2016</b> , 3, 1-88	1.7	1
129	Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants. <i>International Journal of COPD</i> , <b>2016</b> , 11, 2409-2417	3	18
128	Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls. <i>International Journal of COPD</i> , <b>2016</b> , 11, 2139-2147	3	13
127	Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility. <i>International Journal of COPD</i> , <b>2016</b> , 11, 2035-40	3	6
126	Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. <i>International Journal of COPD</i> , <b>2016</b> , 11, 2885-2895	3	16



125	Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO studies. <i>Respiratory Research</i> , <b>2016</b> , 17, 73	7.3	33
124	Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. <i>International Journal of COPD</i> , <b>2016</b> , 11, 1413-24	3	47
123	Leukotriene B4 levels in sputum from asthma patients. <i>ERJ Open Research</i> , <b>2016</b> , 2,	3.5	13
122	Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. <i>BMJ Open</i> , <b>2016</b> , 6, e007709	3	43
121	Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography. <i>European Respiratory Journal</i> , <b>2016</b> , 48, 92-103	13.6	35
120	The prevalence of small airways disease in adult asthma: A systematic literature review. <i>Respiratory Medicine</i> , <b>2016</b> , 116, 19-27	4.6	64
119	Anti-inflammatory potential of PI3K and JAK inhibitors in asthma patients. <i>Respiratory Research</i> , <b>2016</b> , 17, 124	7.3	29
118	Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 31, 85-91	3.5	6
117	High- and low-dose allergen challenges in asthmatic patients using inhaled corticosteroids. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 523-32	3.8	4
116	The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. <i>Thorax</i> , <b>2015</b> , 70, 757-63	7.3	10
115	Different inhaled allergen challenge models give reproducible results. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 33, 57-8	3.5	3
114	Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 756-66	3.8	19
113	Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 492-500	3.8	24
112	Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. <i>Lancet, The</i> , <b>2015</b> , 385, 1789-1798	4.0	168
111	The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. <i>Mucosal Immunology</i> , <b>2015</b> , 8, 1021-1030	9.2	68
110	Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. <i>BMC Pulmonary Medicine</i> , <b>2015</b> , 15, 91	3.5	42
109	Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 1312-9	4.6	122
108	Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1175-84	2.8	28

107	The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 501-2.e6	11.5	9
106	The role of CRAC channel in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 35, 67-74	3.5	5
105	The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 30, 102-9	3.5	5
104	New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 695-708	3.8	49
103	Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 1200-10	5.6	33
102	Chronic Obstructive Pulmonary Disease, Neutrophils and Bacterial Infection: A Complex Web Involving IL-17 and IL-22 Unravels. <i>EBioMedicine</i> , <b>2015</b> , 2, 1580-1	8.8	5
101	Gene expression changes caused by the p38 MAPK inhibitor dilmapiomod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial. <i>Pharmacology Research and Perspectives</i> , <b>2015</b> , 3, e00094	3.1	13
100	Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). <i>Respiratory Research</i> , <b>2015</b> , 16, 92	7.3	85
99	The effects of corticosteroids on COPD lung macrophages: a pooled analysis. <i>Respiratory Research</i> , <b>2015</b> , 16, 98	7.3	30
98	Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , <b>2015</b> , 10, 293-307	3	18
97	MR Quantitative Equilibrium Signal Mapping: A Reliable Alternative to CT in the Assessment of Emphysema in Patients with Chronic Obstructive Pulmonary Disease. <i>Radiology</i> , <b>2015</b> , 275, 579-88	20.5	11
96	Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 523-5	10.2	273
95	Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 767-76	3.8	13
94	Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity <b>2015</b> ,		2
93	Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo <b>2015</b> ,		2
92	Corticosteroid effects on COPD alveolar macrophages: dependency on cell culture methodology. <i>Journal of Immunological Methods</i> , <b>2014</b> , 405, 144-53	2.5	12
91	Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. <i>European Journal of Radiology</i> , <b>2014</b> , 83, 2093-101	4.7	23
90	Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 1156-65	13.6	44

89	Repeatability of induced sputum measurements in moderate to severe asthma. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 1566-8	4.6	9
88	The effect of inhaled IFN- $\gamma$ on worsening of asthma symptoms caused by viral infections. A randomized trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 190, 145-54	10.2	182
87	Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. <i>Respiratory Research</i> , <b>2014</b> , 15, 103	7.3	38
86	Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. <i>BMC Pulmonary Medicine</i> , <b>2014</b> , 14, 43	3.5	32
85	Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study. <i>Chest</i> , <b>2014</b> , 145, 375A	5.3	7
84	Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. <i>BMC Pulmonary Medicine</i> , <b>2014</b> , 14, 178	3.5	138
83	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. <i>BMC Pulmonary Medicine</i> , <b>2014</b> , 14, 166	3.5	15
82	CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patients. <i>Clinical Science</i> , <b>2014</b> , 126, 223-32	6.5	10
81	The effects of corticosteroids on cytokine production from asthma lung lymphocytes. <i>International Immunopharmacology</i> , <b>2014</b> , 23, 581-4	5.8	12
80	Eosinophilic inflammation in COPD: prevalence and clinical characteristics. <i>European Respiratory Journal</i> , <b>2014</b> , 44, 1697-700	13.6	257
79	A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting $\beta$ -adrenergic agonist, in asthma; a Phase II, randomized study. <i>BMC Pulmonary Medicine</i> , <b>2014</b> , 14, 176	3.5	11
78	The effect of peroxisome proliferator-activated receptor- $\gamma$ ligands on in vitro and in vivo models of COPD. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 409-20	13.6	66
77	Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. <i>PLoS ONE</i> , <b>2014</b> , 9, e107381	3.7	38
76	The reproducibility of bolus allergen challenges; power calculations for clinical trials. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 1187-8	2.8	2
75	Critical assessment of the value of sputum neutrophils. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2013</b> , 10, 107-14	2	5
74	Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. <i>Lancet Respiratory Medicine</i> , <b>2013</b> , 1, 714-27	35.1	98
73	Predictors of objective cough frequency in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 943-9	10.2	62
72	The role of the liver X receptor in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2013</b> , 14, 106	7.3	23

71	Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 28-41	13.6	68
70	A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. <i>European Respiratory Journal</i> , <b>2013</b> , 41, 12-7	13.6	21
69	Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2013</b> , 347, 173-80	4.7	47
68	Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. <i>European Respiratory Journal</i> , <b>2013</b> , 41, 46-52	13.6	77
67	Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose-response study. <i>International Journal of General Medicine</i> , <b>2013</b> , 6, 897-903	2.3	8
66	Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. <i>PLoS ONE</i> , <b>2013</b> , 8, e71629	3.7	25
65	Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. <i>PLoS ONE</i> , <b>2013</b> , 8, e64257	3.7	13
64	Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. <i>Current Drug Targets</i> , <b>2013</b> , 14, 235-45	3	19
63	T lymphocyte insensitivity to corticosteroids in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , <b>2012</b> , 13, 20	7.3	23
62	Relief of methacholine-induced bronchospasm with extrafine beclomethasone dipropionate/formoterol in comparison with salbutamol in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2012</b> , 25, 392-8	3.5	8
61	The nuclear receptor REV-ERB $\alpha$ mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 582-7	11.5	409
60	Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , <b>2012</b> , 6, 581-8	3.8	2
59	Reduced glucocorticoid receptor expression and function in airway neutrophils. <i>International Immunopharmacology</i> , <b>2012</b> , 12, 26-33	5.8	32
58	LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. <i>International Immunopharmacology</i> , <b>2012</b> , 13, 225-31	5.8	25
57	Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. <i>Respiratory Research</i> , <b>2012</b> , 13, 72	7.3	65
56	Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. <i>British Journal of Clinical Pharmacology</i> , <b>2012</b> , 74, 1023-32	3.8	25
55	Diesel exhaust particle exposure in vitro alters monocyte differentiation and function. <i>PLoS ONE</i> , <b>2012</b> , 7, e51107	3.7	18
54	Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. <i>International Journal of COPD</i> , <b>2012</b> , 7, 503-13	3	100

53	A comparison of the clinical and induced sputum characteristics of early- and late-onset asthma. <i>Lung</i> , <b>2012</b> , 190, 459-62	2.9	11
52	The EvA study: aims and strategy. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 823-9	13.6	22
51	Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2012</b> , 303, L929-38	5.8	65
50	Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 830-6	13.6	148
49	P189 Reduced COPD Exacerbations Associated with Acclidinium Bromide Versus Placebo: A Pooled Analysis of Phase III Data. <i>Thorax</i> , <b>2012</b> , 67, A146.1-A146	7.3	3
48	Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. <i>Allergy and Asthma Proceedings</i> , <b>2012</b> , 33, 140-4	2.6	14
47	Non-invasive phenotyping using exhaled volatile organic compounds in asthma. <i>Thorax</i> , <b>2011</b> , 66, 804-9	7.3	140
46	Safety of indacaterol in the treatment of patients with COPD. <i>International Journal of COPD</i> , <b>2011</b> , 6, 477-92	3	46
45	Genetics of sputum gene expression in chronic obstructive pulmonary disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e24395	3.7	48
44	Loss of glucocorticoid receptor expression by DNA methylation prevents glucocorticoid induced apoptosis in human small cell lung cancer cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e24839	3.7	34
43	Identification of cells expressing IL-17A and IL-17F in the lungs of patients with COPD. <i>Chest</i> , <b>2011</b> , 139, 1089-1100	5.3	92
42	Effect of AeroChamber Plus <sup>®</sup> on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 72, 932-9	3.8	15
41	Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD. <i>Respiratory Research</i> , <b>2011</b> , 12, 3	7.3	71
40	Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. <i>Thorax</i> , <b>2011</b> , 66, 489-95	7.3	48
39	Increased airway T regulatory cells in asthmatic subjects. <i>Chest</i> , <b>2010</b> , 138, 905-12	5.3	53
38	Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 1049-60	10.2	60
37	A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. <i>Journal of Clinical Pharmacology</i> , <b>2010</b> , 50, 94-100	2.9	67
36	Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. <i>Analyst</i> , <b>2010</b> , 135, 315-20	5	106

35	Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. <i>Respiratory Research</i> , <b>2010</b> , 11, 77	7.3	111
34	The effects of dexamethasone on cigarette smoke induced gene expression changes in COPD macrophages. <i>International Immunopharmacology</i> , <b>2010</b> , 10, 57-64	5.8	20
33	Role of T Regulatory Cells in the Pathogenesis of Asthma: Response. <i>Chest</i> , <b>2010</b> , 138, 1283	5.3	
32	The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. <i>Respiratory Research</i> , <b>2010</b> , 11, 26	7.3	72
31	A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. <i>BMC Pulmonary Medicine</i> , <b>2010</b> , 10, 3	3.5	69
30	Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. <i>International Journal of COPD</i> , <b>2010</b> , 5, 197-208	3	47
29	The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. <i>International Journal of COPD</i> , <b>2009</b> , 4, 149-56	3	34
28	Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor	4.7	44
27	alpha,beta-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2009</b> , 296, L839-48	5.8	83
26	Seretide withdrawal increases airway inflammation in moderate COPD patients. <i>European Journal of Clinical Pharmacology</i> , <b>2009</b> , 65, 1165-6	2.8	6
25	Reduced exhaled breath condensate pH in asthmatic smokers using inhaled corticosteroids. <i>Respirology</i> , <b>2009</b> , 14, 419-23	3.6	13
24	Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 136-43	4.6	70
23	Prevalence of airflow obstruction in patients attending a rapid access chest pain clinic. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 736-42	4.6	1
22	Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. <i>Respiratory Medicine</i> , <b>2009</b> , 103, 1572-9	4.6	59
21	COPD phenotype description using principal components analysis. <i>Respiratory Research</i> , <b>2009</b> , 10, 41	7.3	44
20	Cyclic hydrostatic pressure and cotton particles stimulate synthesis by human lung macrophages of cytokines in vitro. <i>Respiratory Research</i> , <b>2009</b> , 10, 44	7.3	2
19	The effects of smoking on the lipopolysaccharide response and glucocorticoid sensitivity of alveolar macrophages of patients with asthma. <i>Chest</i> , <b>2009</b> , 136, 163-170	5.3	8
18	The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 244-52	3.8	55



17	The reproducibility of adenosine monophosphate bronchial challenges in mild, steroid-naïve asthmatics. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 66, 261-5	3.8	4
16	Tolerability of high cumulative doses of the HFA modulate beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2008</b> , 21, 551-7	3.5	15
15	Cigarette smoke extract induced cytokine and chemokine gene expression changes in COPD macrophages. <i>Cytokine</i> , <b>2008</b> , 42, 205-216	4	50
14	Novel anti-inflammatory treatments for asthma. <i>Expert Review of Respiratory Medicine</i> , <b>2008</b> , 2, 617-29	3.8	4
13	MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 1033-9	10.2	104
12	Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. <i>Journal of Endocrinology</i> , <b>2008</b> , 198, 499-509	4.7	55
11	Non-invasive biomarkers and pulmonary function in smokers. <i>International Journal of COPD</i> , <b>2008</b> , 3, 171-83	3	28
10	Tiotropium; more knowledge leads to more questions. <i>International Journal of COPD</i> , <b>2008</b> , 3, i-ii	3	1
9	Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. <i>Respiratory Research</i> , <b>2007</b> , 8, 52	7.3	16
8	CD4-regulatory cells in COPD patients. <i>Chest</i> , <b>2007</b> , 132, 156-63	5.3	90
7	Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 176, 988-93	10.2	113
6	A comparison of exhaled nitric oxide measurements performed using three different analysers. <i>Respiratory Medicine</i> , <b>2006</b> , 100, 1392-6	4.6	52
5	A comparison of lung function methods for assessing dose-response effects of salbutamol. <i>British Journal of Clinical Pharmacology</i> , <b>2004</b> , 58, 134-41	3.8	57
4	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. <i>Transplantation</i> , <b>2004</b> , 77, 557-61	1.8	17
3	Tuberculin test measurement: variability due to the time of reading. <i>Chest</i> , <b>2002</b> , 122, 1299-301	5.3	16
2	Repeat tuberculin testing in BCG-vaccinated subjects in the United Kingdom. The booster effect varies with the time of reading. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2001</b> , 164, 962-4	10.2	14
1	A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1		3